Acquisition History / Gilead Sciences, Inc. / Arcellx, Inc.
Gilead Sciences, Inc. Acquires Arcellx, Inc.
Announced February 23, 2026 — $7.80B
What happened
Gilead agreed on February 23, 2026 to acquire cell-therapy developer Arcellx for $115 per share in cash at closing plus a $5 contingent value right, an implied equity value of $7.8B payable at closing and a 68% premium to the 30-day VWAP, via tender offer for shares Gilead does not already own.
- Acquirer
- Gilead Sciences, Inc.
- Target
- Arcellx, Inc.
- Announced
- February 23, 2026
- Price
- $7.80B
- Industry
- Cell therapy biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Gilead Sciences, Inc. acquire Arcellx, Inc.?
Gilead Sciences, Inc. acquired Arcellx, Inc. on February 23, 2026. This was Gilead Sciences, Inc.'s 1st publicly tracked acquisition out of 1 we have on record.
How much did Gilead Sciences, Inc. pay for Arcellx, Inc.?
Gilead Sciences, Inc. paid $7.80B for Arcellx, Inc..
What does Arcellx, Inc. do?
Gilead agreed on February 23, 2026 to acquire cell-therapy developer Arcellx for $115 per share in cash at closing plus a $5 contingent value right, an implied equity value of $7.8B payable at closing and a 68% premium to the 30-day VWAP, via tender offer for shares Gilead does not already own.
What other Cell therapy biotechnology companies has Gilead Sciences, Inc. acquired?
Arcellx, Inc. is Gilead Sciences, Inc.'s only publicly tracked acquisition in Cell therapy biotechnology so far.